(Q53157925)
Statements
191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. (English)
S Peters
S Antonia
S B Goldberg
J V Heymach
E S Kim
K Nakagawa
V Papadimitrakopoulou
P Mukhopadhyay
S McIntosh
N A Rizvi
15 April 2016
11
4 Suppl
S139-40